SWOG clinical trial number
SWOG-9501

A Phase II Trial of Fludarabine and Mitoxantrone (FN) for Treatment of Non-Hodgkin's Lymphoma

Closed
Phase
Accrual
100%
Published
Abbreviated Title
A Phase II Trial of Fludarabine and Mitoxantrone (FN) for Treatment of Non-Hodgkin's Lymphoma
Activated
04/01/1995
Closed
02/15/1996

Research committees

Lymphoma

Publication Information Expand/Collapse

2003

Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501

WS Velasquez;D Lew;TM Grogan;CH Spiridonidis;SP Balcerzak;SR Dakhil;TP Miller;K Lanier;RA Chapman;RI Fisher Journal of Clinical Oncology 21(10):1996-2003

1999

SWOG 95-01: A phase II trial of a combination of fludarabine and mitoxantrone (FN) in untreated advanced low grade lymphoma. An effective, well tolerated therapy.

W Velasquez;D Lew;T Miller;R Fisher Proc of the American Society of Clinical Oncology 18:9a(#27)

Other Clinical Trials

SWOG Clinical Trial Number
S2506

MOZART MZL: A Randomized Phase II Study with a Common Control Arm of Mosunetuzumab Monotherapy Evaluated Against Two Experimental Treatment Arms of Either Combination Mosunetuzumab and Zanubrutinib or Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients with Relapsed/Refractory Marginal Zone Lymphoma
Research Committee(s)
Lymphoma
Activated
08/18/2026
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA4232

A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Research Committee(s)
Lymphoma
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2308

Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
69%
Open
Phase